A phase 2a, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and pharmacodynamic effects of biib122 in participants with lrrk2-associated parkinson’s disease (lrrk2-pd)

• Protocol code: DNLI-C-0009
• EudraCT code: _
• Research group: Neurodegenerative Diseases
• Service: Neurology
• Principal investigator:  Hernández Vara, Jorge
• Pathology: Malalties del sistema nerviós
• Phase: Fase II
• Status: Recruiting volunteers

A Randomized, Double-masked, Multicenter, 3-Arm Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema

• Protocol code: EYE-RES-102
• EudraCT code: No aplica
• Research group: Ophtalmology
• Service: Ophthalmology
• Principal investigator:  Garrido Marin, Marta
• Pathology: Malalties de l’ull i dels seus annexos
• Phase: Fase III
• Status: Recruiting volunteers

Estudio de fase 1 del inhibidor de menina ziftomenib en combinación con quimioterapia en niños con leucemia aguda recidivante o resistente al tratamiento con reordenamientos de los genes KMT2A o NUP98, o con mutación en el gen NPM1

• Protocol code: ITCC-101/APAL2020K
• EudraCT code: No aplica
• Research group: Childhood Cancer and Blood Disorders
• Service: Pediatric Oncohematology
• Principal investigator:  Murillo Sanjuán , Laura
• Pathology: Tumors
• Phase: Fase I

Estudio clínico de fase 3, aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la seguridad de molnupiravir (MK-4482) en adultos no hospitalizados con COVID-19 y alto riesgo de progresión de la enfermedad

• Protocol code: MK-4482-023
• EudraCT code: No aplica
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Len Abad, Oscar
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase III

A Phase 2a, Open-label, Multicenter, Platform Trial to Assessthe Safety, Tolerability, and Efficacy of Inebilizumab andBlinatumomab in Subjects With Select Autoimmune Diseases

• Protocol code: 20240033
• EudraCT code: No aplica
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Bestard Matamoros, Oriol
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II